Association between persistence with statin therapy and reduction in low-density lipoprotein cholesterol level: Analysis of real-life data from community settings

Pharmacotherapy

Volumn 34, Issue 1, 2014, Pages 1-8

  Shalev, Varda ^a,b   Goldshtein, Inbal ^a   Halpern, Yair ^b   Chodick, Gabriel ^a,b  

^a MACCABI HEALTHCARE SERVICES   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Adherence; Coronary heart disease; Goal attainment; Lipids; Persistence; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DRUG EXPOSURE; DRUG USE; FEMALE; FOLLOW UP; HEALTH CARE CONCEPTS; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PROPORTION OF DAYS COVERED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADHERENCE; CORONARY HEART DISEASE; GOAL ATTAINMENT; LIPIDS; PERSISTENCE; STATINS;

AGED; CHOLESTEROL, LDL; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; POPULATION SURVEILLANCE; PRIMARY PREVENTION; RESIDENCE CHARACTERISTICS; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; STATISTICS AS TOPIC;

EID: 84898020616     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1326     Document Type: Article

References (31)

1. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003;23: 686-9.
2. Shakir S. Prescription-event monitoring. In: Strom B, ed. Pharmacoepidemiology. Chichester, UK: Wiley & Sons, Ltd., 2005: 203-16.
3. Fincham JE. Patient compliance with medications: issues and opportunities. Binghamton, NY: Haworth Press; 2007.
4. McKenzie DA, Semradek J, McFarland BH, Mullooly JP, McCamant LE. The validity of medicaid pharmacy claims for estimating drug use among elderly nursing home residents: the Oregon experience. J Clin Epidemiol 2000;53: 1248-57.
5. Grymonpre R, Cheang M, Fraser M, Metge C, Sitar DS. Validity of a prescription claims database to estimate medication adherence in older persons. Med Care 2006;44: 471-7.
6. Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999;37: 846-57.
7. Benner JS, Pollack MF, Smith TW, Bullano MF, Willey VJ, Williams SA. Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health Syst Pharm 2005;62: 1468-75.
8. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326: 1423.
9. Ray K, Seshasai S, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 2010;170: 1024-31.
10. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333: 1301-7.
11. Thavendiranathan P, Bagai A, Brookhart MA, et al. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 2006;166: 2307-13.
12. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998;279: 1458-62.
13. Chodick G, Shalev V, Gerber Y, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008;30: 2167-79.
14. Cutler DM, Everett W. Thinking outside the pillbox-medication adherence as a priority for health care reform. N Engl J Med 2010;362: 1553-5.
15. Shalev V, Chodick G, Silber H, Kokia E, Jan J, Heymann AD. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med 2009;169: 260-8.
16. Shalev V, Chodick G, Goren I, Silber H, Kokia E, Heymann AD. The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization. Int J Cardiol 2011;152: 345-9.
17. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW. Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy 2005;25: 1035-43.
18. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11: 44-7.
19. Ruokoniemi P, Korhonen MJ, Helin-Salmivaara A, et al. Statin adherence and the risk of major coronary events in patients with diabetes: a nested case-control study. Br J Clin Pharmacol 2011;71: 766-76.
20. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment, 14 ed. Geneva: World Health Organization, 2011.
21. National Heart, Lung, and Blood Institute. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final Report. Washington, DC: National Institutes of Health, NHLBI. NIH Publication No. 02-5215. 2002.
22. Dart A, Jerums G, Nicholson G, et al. A multicenter, doubleblind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997;80: 39-44.
23. Davidson M, McKenney J, Stein E, et al. Comparison of oneyear efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 1997;79: 1475-81.
24. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92: 152-60.
25. But A, Suvisaari J, Suvisaari J, Niskanen L, Jari H. A Comparison of the Effectiveness of Statins in Reducing Total Cholesterol and Low-Density Lipoprotein Cholesterol. 28th International Conference on Pharmacotherapy and Therapeutics Risk Management Barcelona, Spain, 2012.
26. Patel JV, Hughes EA. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia. Int J Clin Pract 2006;60: 914-21.
27. Ray K, Seshasai S, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 2010;170: 1024-31.
28. Heintjes E, Penning-van Beest F, Plat A, et al. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice. Pharmacotherapy 2012;32: 631-4.
29. Van Ganse E, Laforest L, Alemao E, Davies G, Gutkin S, Yin D. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005;21: 1389-99.
30. Deambrosis P, Terrazzani G, Walley T, et al. Benefit of statins in daily practice? A six-year retrospective observational study. Pharmacol Res 2009;60: 397-407.
31. Chodick G, Shalev V, Gerber Y, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008;30: 2167-79.